Evolus, Inc. (EOLS) Stock Grade

About Evolus, Inc.'s fundamentals

Evolus is a specialty pharmaceutical company with a market capitalization of $428.7 million that has demonstrated solid revenue growth of 11.6% year-over-year. However, the company is currently unprofitable, posting a net margin of -17.4% in its latest annual statement, which explains why a P/E ratio is not available. The company does not pay a dividend and shows a return on equity of 223.5%, a metric that can be distorted when companies have minimal or negative earnings. Investors should note that Evolus is in a growth phase while working toward profitability.